A detailed history of Israel Englander (Millennium Management LLC) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 3,005,598 shares of ACRS stock, worth $11.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,005,598
Previous 3,336,850 9.93%
Holding current value
$11.9 Million
Previous $3.67 Million 7.47%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.12 - $1.4 $371,002 - $463,752
-331,252 Reduced 9.93%
3,005,598 $3.4 Million
Q2 2024

Aug 14, 2024

BUY
$1.01 - $1.36 $63,991 - $86,166
63,358 Added 1.94%
3,336,850 $3.67 Million
Q1 2024

May 15, 2024

SELL
$0.92 - $1.44 $189,399 - $296,451
-205,869 Reduced 5.92%
3,273,492 $4.06 Million
Q4 2023

Feb 14, 2024

BUY
$0.64 - $6.49 $1.7 Million - $17.2 Million
2,652,277 Added 320.68%
3,479,361 $3.65 Million
Q2 2023

Aug 14, 2023

BUY
$7.89 - $10.64 $6.05 Million - $8.15 Million
766,221 Added 1258.93%
827,084 $8.58 Million
Q1 2023

May 15, 2023

SELL
$7.07 - $17.95 $1.04 Million - $2.64 Million
-147,035 Reduced 70.72%
60,863 $492,000
Q4 2022

Feb 14, 2023

BUY
$14.33 - $18.37 $57,219 - $73,351
3,993 Added 1.96%
207,898 $3.27 Million
Q3 2022

Nov 14, 2022

BUY
$13.07 - $18.22 $66,800 - $93,122
5,111 Added 2.57%
203,905 $3.21 Million
Q2 2022

Aug 15, 2022

BUY
$10.16 - $17.08 $1.45 Million - $2.44 Million
142,581 Added 253.64%
198,794 $2.78 Million
Q1 2022

May 16, 2022

SELL
$9.74 - $17.92 $2.89 Million - $5.31 Million
-296,294 Reduced 84.05%
56,213 $969,000
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.49 $384,247 - $579,032
31,316 Added 9.75%
352,507 $5.13 Million
Q3 2021

Nov 15, 2021

BUY
$13.38 - $18.8 $1.62 Million - $2.27 Million
120,827 Added 60.3%
321,191 $5.78 Million
Q2 2021

Aug 16, 2021

SELL
$17.08 - $29.6 $2.44 Million - $4.23 Million
-142,883 Reduced 41.63%
200,364 $3.52 Million
Q1 2021

May 17, 2021

BUY
$5.86 - $27.73 $787,121 - $3.72 Million
134,321 Added 64.29%
343,247 $8.65 Million
Q4 2020

Feb 16, 2021

SELL
$2.65 - $7.61 $193,110 - $554,555
-72,872 Reduced 25.86%
208,926 $1.35 Million
Q3 2020

Nov 16, 2020

SELL
$1.5 - $2.71 $154,705 - $279,501
-103,137 Reduced 26.79%
281,798 $724,000
Q2 2020

Aug 14, 2020

BUY
$1.04 - $1.73 $400,332 - $665,937
384,935 New
384,935 $624,000
Q1 2020

May 14, 2020

SELL
$0.75 - $2.18 $211,386 - $614,428
-281,848 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.02 - $1.97 $21,824 - $42,152
21,397 Added 8.22%
281,848 $533,000
Q3 2019

Nov 14, 2019

BUY
$0.79 - $2.47 $177,801 - $555,910
225,065 Added 636.03%
260,451 $281,000
Q2 2019

Aug 15, 2019

SELL
$2.13 - $7.06 $264,618 - $877,092
-124,234 Reduced 77.83%
35,386 $77,000
Q2 2019

Aug 14, 2019

BUY
$2.13 - $7.06 $295,469 - $979,349
138,718 Added 663.66%
159,620 $5.3 Million
Q1 2019

May 14, 2019

BUY
$5.63 - $7.84 $117,678 - $163,871
20,902 New
20,902 $125,000
Q2 2018

Aug 14, 2018

SELL
$16.46 - $20.33 $1.82 Million - $2.25 Million
-110,827 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$17.08 - $25.64 $1.69 Million - $2.54 Million
99,029 Added 839.37%
110,827 $1.94 Million
Q4 2017

Feb 14, 2018

BUY
$21.47 - $27.8 $253,303 - $327,984
11,798
11,798 $291,000

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $264M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.